Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/123545
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Serelaxin: a novel therapeutic for vascular diseases |
Author: | Leo, C.H. Jelinic, M. Ng, H.H. Tare, M. Parry, L.J. |
Citation: | Trends in Pharmacological Sciences, 2016; 37(6):498-507 |
Publisher: | Elsevier |
Issue Date: | 2016 |
ISSN: | 0165-6147 1873-3735 |
Statement of Responsibility: | Chen Huei Leo, Maria Jelinic, Hooi Hooi Ng, MarianneTare, Laura J.Parry |
Abstract: | Vascular dysfunction is an important hallmark of cardiovascular disease. It is characterized by increased sensitivity to vasoconstrictors, decreases in the endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH). Serelaxin (recombinant human relaxin) has gained considerable attention as a new vasoactive drug, largely through its beneficial therapeutic effects in acute heart failure. In this review we first describe the contribution of endogenous relaxin to vascular homeostasis. We then provide a comprehensive overview of the novel mechanisms of serelaxin action in blood vessels that differentiate it from other vasodilator drugs and explain how this peptide could be used more widely as a therapeutic to alleviate vascular dysfunction in several cardiovascular diseases. |
Keywords: | Serelaxin; vascular dysfunction; endothelium; prostanoids; nitric oxide |
Rights: | © 2016 Published by Elsevier Ltd. |
DOI: | 10.1016/j.tips.2016.04.001 |
Grant ID: | NHMRC |
Published version: | http://dx.doi.org/10.1016/j.tips.2016.04.001 |
Appears in Collections: | Aurora harvest 4 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.